Description
A dual inhibitor of FTase and GGTase I (IC50s = 2 and 98 nM, respectively); inhibits prenylation of FTase and GGTase I substrates HDJ2 and RAP1A in PSN-1 pancreatic tumor cells (EC50s = 92 and 6,760 nM, respectively); inhibits prenylation of the oncogenic protein KI-RAS in PSN-1 cells in a concentration-dependent manner; reduces HDJ2 and RAP1A prenylation ex vivo in dog PBMCs when administered at a dose of 35-50 mg/kg per day; has no effect on KI-RAS prenylation in patient-derived PBMCs; inhibits lectin-induced expression of the T cell activation markers CD71 and CD25 on human PMBCs (IC50s = 6.48 and 84.1 μM, respectively); inhibits IL-2-induced proliferation of CTLL-2 cells (IC50 = 0.81 μM)
Formal name: 4-[[5-[[4-(3-chlorophenyl)-3-oxo-1-piperazinyl]methyl]-1H-imidazol-1-yl]methyl]-benzonitrile, monohydrochloride
Synonyms:
Molecular weight: 442.3
CAS: 253863-00-2
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Small Molecule Inhibitors||Research Area|Cancer||Research Area|Immunology & Inflammation|Adaptive Immunity||Research Area|Immunology & Inflammation|Innate Immunity
